CoChat

Neuropathy: The Crystal Ball for Cardiovascular Disease?

Open access
Vinik, Aaron I., Maser, Raelene E., Ziegler, Dan · 2010 · Diabetes Care
Cited by 84

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Cardiovascular disease (CVD) is a major cause of death in patients with type 2 diabetes. Unclear, however, is the effect of intensive therapy in reducing the development of cardiovascular complications. The UK Prospective Diabetes Study (UKPDS), involving patients with newly diagnosed disease, showed a nonsignificant trend in the reduction of rates for myocardial infarction (MI) (1). However, data 10 years after cessation of the trial showed a 15% reduction in the risk of MI for those in the original intensive therapy group (2). This benefit from early intensive therapy persisted despite the fact that the within-trial differences for A1C between the intensive and conventional therapy groups were lost within 1 year of completion of the trial. The sustained benefit from early aggressive treatment is referred to as the legacy effect or metabolic memory. The question of more intensive therapy and reduction in cardiovascular complications was addressed for people with type 2 diabetes of long duration in three other studies (i.e., the Action to Control Cardiovascular Risk in Diabetes [ACCORD] [3], the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE] [4], the Veterans Affairs Diabetes Trial [VADT] [5]). Although the three studies utilized different patient cohorts, with varying durations of diabetes (ACCORD, 10 years; VADT, 11.5 years; and ADVANCE, 8 years) and had different treatment regimens, the results of these trials indicated that intensive glucose control did not reduce CVD events. In fact, the ACCORD trial was terminated early because an increased rate of mortality was found to be associated with intensive control of hyperglycemia (6). A higher rate of mortality for those on intensive treatment was not, however, found in ADVANCE and VADT. Recent articles from the ACCORD trial, by Pop-Busui et al. (7) and Calles Escandon et …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-0745

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 84

Metadata

Authors
Vinik, A. I., Maser, R. E., & Ziegler, D.
Venue
Diabetes Care
Published
2010-07-01
Volume
33
Issue
7
Pages
1688-1690
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1974667696
Cited by
84
References
10
FWCI
4.84
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuropathy: The Crystal Ball for Cardiovascular Disease? https://app.cochat.ai/papers/10.2337/dc10-0745
The paper
Vinik, A. I., Maser, R. E., & Ziegler, D. (2010). Neuropathy: The Crystal Ball for Cardiovascular Disease? Diabetes Care. https://doi.org/10.2337/dc10-0745

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.